摘要
原發性高醛固酮症（primary aldosteronism, PA）來自於腎上腺皮質分泌過多的醛固酮，是最常見的內分泌高血壓（endocrine hypertension）原因之一。原發性高醛固酮症最常見的亞型包括醛固酮單側腺瘤（aldosterone‑producing adenoma, APA）及雙側腎上腺增生（bilateral adrenal hyperplasia, BAH），前者大多可因單側腎上腺切除而治癒，後者以醛固酮受體阻抗劑治療為主。在過去的十年中，隨著研究的進展，術前腎上腺切除術結果的預測因子以及術後復發或治療失敗的風險因子，包括組織病理學診斷和基因突變檢測，已被確定與原發性高醛固酮症的手術預後相關。因此，我們可以鑑別出術後治療失敗機率高或復發風險高的患者並加強追蹤。
參考文獻
Chen YY, Huang SC, Pan CT, et al. The predictors of long-term outcomes after targeted therapy for primary Aldosteronism. J Formos Med assoc 2024:123:S135-40.
Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013;62:62-9.
Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017;5:689-99.
Williams TA, Gomez-Sanchez CE, Rainey WE, et al. International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 2021;106:42-54.
Juhlin CC, Bertherat J, Giordano TJ, et al. What did we learn from the molecular biology of adrenal cortical neoplasia? From histopathology to translational genomics. Endocr Pathol 2021;32:102-33.